EP4469059A4 - Pharmazeutische zusammensetzungen aus mycophenolsäure und/oder betamethason zur behandlung von augenerkrankungen - Google Patents

Pharmazeutische zusammensetzungen aus mycophenolsäure und/oder betamethason zur behandlung von augenerkrankungen

Info

Publication number
EP4469059A4
EP4469059A4 EP23743806.4A EP23743806A EP4469059A4 EP 4469059 A4 EP4469059 A4 EP 4469059A4 EP 23743806 A EP23743806 A EP 23743806A EP 4469059 A4 EP4469059 A4 EP 4469059A4
Authority
EP
European Patent Office
Prior art keywords
betamethasone
treatment
pharmaceutical compositions
mycophenolic acid
eye diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23743806.4A
Other languages
English (en)
French (fr)
Other versions
EP4469059A2 (de
Inventor
Kamran Hosseini
Richard Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surface Ophthalmics Inc
Original Assignee
Surface Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/582,627 external-priority patent/US20220143075A1/en
Application filed by Surface Ophthalmics Inc filed Critical Surface Ophthalmics Inc
Publication of EP4469059A2 publication Critical patent/EP4469059A2/de
Publication of EP4469059A4 publication Critical patent/EP4469059A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP23743806.4A 2022-01-24 2023-01-23 Pharmazeutische zusammensetzungen aus mycophenolsäure und/oder betamethason zur behandlung von augenerkrankungen Pending EP4469059A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17/582,627 US20220143075A1 (en) 2017-09-25 2022-01-24 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US202263317770P 2022-03-08 2022-03-08
US202263402704P 2022-08-31 2022-08-31
US202263415419P 2022-10-12 2022-10-12
PCT/US2023/011351 WO2023141334A2 (en) 2022-01-24 2023-01-23 Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
EP4469059A2 EP4469059A2 (de) 2024-12-04
EP4469059A4 true EP4469059A4 (de) 2026-01-21

Family

ID=87349251

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23743806.4A Pending EP4469059A4 (de) 2022-01-24 2023-01-23 Pharmazeutische zusammensetzungen aus mycophenolsäure und/oder betamethason zur behandlung von augenerkrankungen

Country Status (3)

Country Link
EP (1) EP4469059A4 (de)
JP (1) JP2025513090A (de)
WO (1) WO2023141334A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021012492A2 (pt) 2018-12-27 2021-09-08 Surface Ophthalmics, Inc. Composições farmacêuticas oftálmicas e métodos para tratar doença da superfície ocular
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
CN101332180A (zh) * 2008-08-01 2008-12-31 北大方正集团有限公司 霉酚酸滴眼剂及其制备方法
US20150190407A1 (en) * 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
CN104083323B (zh) * 2014-06-27 2016-06-08 新乡医学院 包含妥布霉素和倍他米松的眼用混悬液
JP6871548B2 (ja) * 2016-11-24 2021-05-12 国立大学法人東北大学 濾過胞を維持するための組成物
US11766421B2 (en) * 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
BR112021012492A2 (pt) * 2018-12-27 2021-09-08 Surface Ophthalmics, Inc. Composições farmacêuticas oftálmicas e métodos para tratar doença da superfície ocular
WO2021124301A1 (en) * 2019-12-20 2021-06-24 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
CN117979951A (zh) * 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease", 20 December 2021 (2021-12-20), XP093343697, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT04734197?term=surf-100&rank=1&tab=history&a=3#version-content-panel> *
ANONYMOUS: "Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease", 6 April 2017 (2017-04-06), XP093344326, Retrieved from the Internet <URL:https://investors.harrow.com/node/8231/pdf> *
ANONYMOUS: "Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease", 26 July 2021 (2021-07-26), XP093343681, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT04734210?term=surf-200&rank=1&tab=history&a=2#version-content-panel> *
ANONYMOUS: "Surface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease", 27 January 2021 (2021-01-27), XP093343640, Retrieved from the Internet <URL:https://surfaceophthalmics.com/article/surface-ophthalmics-announces-first-patient-dosed-in-landmark-head-to-head-phase-ii-trial-for-surf-100-for-chronic-dry-eye-disease/> *
ANONYMOUS: "Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye SURF-200 leverages the proven Klarity vehicle and betamethasone corticosteroid to treat acute dry eye", 4 February 2021 (2021-02-04), XP093343655, Retrieved from the Internet <URL:https://surfaceophthalmics.com/article/surface-ophthalmics-announces-first-patient-dosed-in-phase-ii-trial-for-surf-200-for-acute-dry-eye/> *
ANONYMOUS: "Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation Investigational therapy SURF-201 met all primary endpoints for the treatment of pain and inflammation fol", 21 January 2021 (2021-01-21), XP093343647, Retrieved from the Internet <URL:https://surfaceophthalmics.com/article/surface-ophthalmics-announces-positive-top-line-results-from-phase-ii-trial-for-surf-201-betamethasone-0-2-in-klarity-vehicle-for-the-treatment-of-post-cataract-surgery-pain-and-inflammation/> *

Also Published As

Publication number Publication date
WO2023141334A3 (en) 2023-09-21
JP2025513090A (ja) 2025-04-23
WO2023141334A2 (en) 2023-07-27
EP4469059A2 (de) 2024-12-04

Similar Documents

Publication Publication Date Title
EP4469059A4 (de) Pharmazeutische zusammensetzungen aus mycophenolsäure und/oder betamethason zur behandlung von augenerkrankungen
EP3976189C0 (de) Neuartige verbindungen und pharmazeutische zusammensetzungen davon zur behandlung von erkrankungen
EP4329753A4 (de) Pharmazeutische zusammensetzungen und intravitreale wirkstofffreisetzungssysteme zur behandlung von augenerkrankungen
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP4008718C0 (de) Heteroarylamidopyridinolderivate und pharmazeutische zusammensetzungen, die diese umfassen, zur vorbeugung oder behandlung von autoimmunerkrankungen
EP4466022A4 (de) Pharmazeutische formulierungen und verfahren zur behandlung von stoffwechsel- und lebererkrankungen
EP4058017A4 (de) Arzneimittelformulierungen und verfahren zur behandlung von stoffwechselstörungen
EP4000609A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenerkrankungen
EP4215531A4 (de) Verbindung zur prävention und behandlung von lebererkrankungen und pharmazeutische verwendung davon
EP4188346A4 (de) Nobiletinzusammensetzungen und verfahren zur behandlung und prävention von covid-19 und verwandten erkrankungen
EP4159235A4 (de) Pd-1-agonistenhaltige pharmazeutische zusammensetzung zur behandlung oder prävention von th2-vermittelter erkrankung
EP4489746A4 (de) Pharmazeutische zusammensetzungen mit verlängerter freisetzung zur behandlung von augenerkrankungen
EP4433045A4 (de) Formulierungen und verfahren zur behandlung von menopausesymptomen
EP4228696A4 (de) Zusammensetzungen und verfahren zur behandlung von bluterkrankungen
EP4565237A4 (de) Pharmazeutische zusammensetzungen und verwendungen davon zur behandlung von gliom
EP4356916A4 (de) Pharmazeutische zusammensetzung zur linderung oder behandlung von folgen von hirninfarkten
EP4561557A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP4461296A4 (de) Pharmazeutische zusammensetzung zur prävention und/oder behandlung von herzinsuffizienz
EP4582087A4 (de) Pharmazeutische zusammensetzung zur behandlung von lymphomen
EP4415737A4 (de) Zusammensetzungen und verfahren zur behandlung von hauterkrankungen
EP4440567A4 (de) Therapeutische targets und mittel zur behandlung von posttraumatischen stresserkrankungen
EP4201406A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von degenerativen hirnerkrankungen mit abemaciclib als wirkstoff
EP4415714A4 (de) Pridopidin und analoga davon zur behandlung neurodegenerativer augenerkrankungen
EP4412632A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP4374868A4 (de) Pharmazeutische zusammensetzung oder arzneimittelkit zur linderung oder behandlung von fibrotischen erkrankungen und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240826

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251222

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/575 20060101AFI20251216BHEP

Ipc: A61K 9/08 20060101ALI20251216BHEP

Ipc: A61K 31/343 20060101ALI20251216BHEP

Ipc: A61K 47/10 20170101ALI20251216BHEP

Ipc: A61P 27/04 20060101ALI20251216BHEP

Ipc: A61P 27/02 20060101ALI20251216BHEP

Ipc: A61K 9/00 20060101ALI20251216BHEP

Ipc: A61K 31/721 20060101ALI20251216BHEP

Ipc: A61K 31/737 20060101ALI20251216BHEP